Does prolonged anti-inflammatory therapy reduce number of unnecessary repeat saturation prostate biopsy?

Giuseppe Candiano, Pietro Pepe, Francesco Pietropaolo, Francesco Aragona

Urology Unit - Cannizzaro Hospital, Catania, Italy.

Introduction. The effect of a prolonged oral anti-inflammatory therapy on PSA values in patients with persistent abnormal PSA values after negative prostate biopsy (PBx) was evaluated.

Material and methods. From September 2011 to September 2012, 70 patients (median age 62 years), with persistent abnormal PSA values after negative extended PBx, were given an herbal extract with anti-inflammatory activity for 3 months (Lenidase®; 1 tablet daily constituted of bicalina, bromelina and escina). All patients were submitted to prostate biopsy for: abnormal DRE; PSA > 10 ng/mL, PSA values between 4.1-10 or 2.6-4 ng/mL with free/total PSA < 25% and < 20%, respectively. Three months after the end of anti-inflammatory therapy all patients were reevaluated; indication for repeat saturation biopsy (SPBx) and detection rate for PCa were compared with those previously recorded in our Department using the same inclusion criteria for biopsy.

Results. Oral administration of Lenidase® was well tolerated and no side effects were observed; PSA values decreased in 54 (77.8%) out 70 patients with a median PSA reduction of 20.5% (from 8.8 to 7 ng/mL) and remained unchanged in 16 patients (22.2%); the repeat SPBx rate resulted significantly lower (22.8% vs 35.5%; p < 0.05) showing a superimposable detection rate for PCa (3 cases) in comparison with our previous data (18.7% vs 22%).

Conclusions. In our preliminary data a prolonged oral anti-inflammatory therapy reduced PSA levels in patients with negative PBx and persistent suspicious for PCa decreasing the indication to perform repeat SPBx (about 30% of the cases).

KEY WORDS: Prostate cancer; Repeat saturation biopsy; Prostatitis; PSA; Anti-inflammatory therapy.

Submitted 24 September 2012; Accepted 31 December 2012

No conflict of interest declared

INTRODUCTION

The low specificity of PSA test in diagnosing prostate cancer (PCa), especially for serum PSA values < 10 ng/mL, is due to spontaneous fluctuation (1), ejaculation, BPH and acute or subclinical chronic prostatitis (CP). PSA levels have been correlated with the extent and degree of inflammation (2, 3) and a short trial of antibiotics for a likely subclinical CP has some theoretical advantages in decreasing PSA levels (34.6-56% of the cases) (4, 5) thus minimizing the number of biopsies for falsely elevated PSA (20-30% of the cases) (6, 7).

The difference between pre and post-treatment PSA levels appears significant only in benign conditions (BPH and prostatitis cases) while in histologically proven cancer the difference seems unremarkable (8). At the same time, the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin, blocking the cyclooxygenase (COX) activity (a strong mediator of inflammation), could have a potential role in decreasing PSA values. However, the relationship between oral NSAIDs consumption, PSA levels and PCa risk is unknown (9).

In this prospective study we evaluated, in patients with negative extended prostate biopsy and persistent abnormal PSA values, the effect of a prolonged oral anti-inflammatory therapy on PSA values in order to reduce the number of unnecessary repeat biopsies.
MATERIAL AND METHODS

From September 2011 to September 2012, 70 patients (median age 62 years; range: 49-72 years), with previous negative extended prostate biopsy and persistent abnormal PSA values, were given an herbal extract with anti-inflammatory activity (Lenidase®; 1 tablet daily) for 3 months. All patients, 2 months before assuming the herbal extract, underwent prostate biopsy for: abnormal digital rectal examination (DRE); PSA > 10 ng/mL, PSA values between 4.1-10 or 2.6-4 ng/mL with free/total PSA < 25% and < 20%, respectively according to our early diagnosis protocol (10). The biopsy was performed by transperineal approach using a 18 G tru-cut needle guided by a 5-6.5 MHz biplanar transrectal probe (GE Logiq 500 Pro). In case of primary biopsy or repeat saturation biopsy (SBx) a median of 18 (range 16-21) and 28 cores (range 26-35) were taken, respectively. The biopsy protocol included a median of 9-12 cores in the posterior zone of each lobe (Apex, Med and Base) plus 2-4 cores on the transition zone in case of SBx (11). The procedure was performed under sedation and antibiotic prophylaxis. All patients had negative DRE and no-one was symptomatic for acute prostatitis. Patients with previous HGPIN or ASAP were not included; moreover, all patients signed an informed consent form.

Clinical parameters of the patients enrolled in the protocol are listed in Table 1, 37 (52.8%), 18 (25.7%) and 15 (22.5%) men previously underwent one, two and three negative biopsies, respectively. Fifty-eight (64.5%) patients assumed alpha-blockers; none were currently treated with NSAIDs, aspirin, thiazide diuretic, statins, and 5-alfa-reductase inhibitors. At the end of the 3-months course of therapy and after additional 3 months of wash-out, all patients were revaluated with DRE, total PSA, PSA F/T and routine blood test for liver and kidney function. International Prostate Symptoms Score (IPSS) and Qmax before and after anti-inflammatory therapy were recorded. The patients with persistent suspicious for PCa underwent SBx. The repeat SBx rate after anti-inflammatory therapy and detection rate for PCa were compared with those previously recorded in our Department using the same inclusion criteria for biopsy. Finally, a p value < 0.05 was considered statistically significant.

RESULTS

Oral administration of Lenidase® was well tolerated and no side effects were observed. Among 70 patients enrolled, PSA values decreased after anti-inflammatory therapy in 54 (77.8%) with a median PSA reduction of 20.5% (from 8.8 to 7 ng/mL) and remained unchanged in the remaining 16 patients (22.2%). Clinical parameters and serum exams before and after Lenidase® administration are listed in Table 1. All 16 patients whose PSA did not decrease after therapy underwent repeat SBx (6 had a PSA included between 4-10 ng/mL and 10 greater than 10 ng/mL) and in 3 of them a cancer was found (all these men had one previous negative biopsy and a PSA > 10 ng/mL). The incidence of repeat biopsy in the patients submitted to anti-inflammatory therapy resulted significantly lower in comparison with our previous data (22.8% vs 35.5%) (p < 0.05), respectively; on the contrary, the detection rate for PCa was superimposable (18.7% vs 22%) at repeat SBx. IPSS and Qmax values were superimposable before and after anti-inflammatory therapy (p > 0.05) (Table 1).

DISCUSSION

Repeat prostate biopsy constitutes about 30% of all the procedures with an estimated detection rate for PCa equal, in our experience, to 20% and 6% at second and third SBx (10), respectively; today, the main goal of any early diagnosis protocol should be to reduce the number of unnecessary SBx due to false positive PSA levels. The intra-individual (physiological) variation of PSA in men with benign prostate biopsy is equal to 9.5% (12); moreover, many common medications have an effect on serum PSA levels: NSAIDs, thiazide diuretics and statins reduce PSA levels from 6% to 26% and the combination of statins with thiazide diuretics could decrease PSA lev-

| Table 1. | Clinical parameters at baseline and 6 months after anti-inflammatory therapy. |
|---|---|---|---|---|
| 70 patients | Baseline | After therapy | % of reduction | p value |
| Median PSA (ng/mL) | 8.8 (range: 4.6-28) | 7 (range: 2.9-23) | 20.5 | < 0.05 |
| Decreased PSA levels | - | 54 | 77.2 | < 0.05 |
| PSA > 10 | 14 | 10 | 28.5 | < 0.05 |
| PSA 4-10 | 54 | 40 | 26.0 | < 0.05 |
| PSA < 4 | 0 | 20 | 28.5 | < 0.05 |
| IPSS (range) | 13 (4-26) | 12 (5-24) | - | > 0.05 |
| Low (0-7) | 36 | 38 | - | > 0.05 |
| Intermediate (8-19) | 25 | 23 | > 0.05 |
| Severe (20-37) | 9 | 9 | > 0.05 |
| Qmax | 11 ml/sec | 12 ml/sec | - | > 0.05 |
| Urine test | Negative | Negative | - | - |
| Blood test | Normal | Normal | - | - |
Does prolonged anti-inflammatory therapy reduce number of unnecessary repeat saturation prostate biopsy?

el of 36% after 5 years of combined therapy (13-15). Prostatitis is responsible for falsely elevated PSA levels, but it remains unclear in which patients we can avoid repeat biopsy without underestimating the risk of cancer (16). Singer et al. (17) in 1319 men aged > 40 years observed that PSA levels were 24% lower among acetaminophen users compared with non drug takers. Several systematic reviews have examined the relationship between NSAID/ aspirin consumption and the risk of developing PCa. Mahmud et al. (18) in a meta-analysis found that aspirin use provided a 10% risk reduction for PCa and a 30% risk reduction for advanced disease. Harris et al. (19) and Jacobs et al. (20) reported that daily NSAID use (including aspirin) was associated with a 39% and 20% risk reduction for PCa, respectively. Engelhardt and Rjed (21) reported in 20 patients, assuming a daily dose (60 mg) of an isoflavone extract for 1 year, a PSA reduction of 33% combined with a significant increase in hepatic transaminases. All these studies agree that the reduction in PSA levels due to anti-inflammatory therapy may reduce the number of men referred for prostate biopsy decreasing the number of men diagnosed with PCa. However, a clear correlation between NSAIDs, serum PSA and risk of missing a PCa diagnosis is still unknown (16).

In our study, we used as anti-inflammatory agent a mixture of herbal extract (Lenidase®) which has a demonstrated antiedematous and anti-inflammatory activity. Each tablet contains: baicalina (190 mg), a flavonoid from Scutellaria baicalensis that inhibits 5-lipoxygenase (5-LOX) and COX activities and leukotriene synthesis (22-24), bromelina (50 mg), extract from Ananas comosus, that is an enzymatic anti-inflammatory agent and escina (30 mg), extract from Aesculus hippocastanum, that has an antiedemigene effect and enhances corticosteroid receptors activity. A median PSA reduction of about 20% was observed in 54/70 (77.2%) patients assuming Lenidase®. In details, 15 (28.5%) men reached a PSA value < 4 ng/mL and the repeat SPBx rate resulted significantly lower in comparison with our previous data (22.8% vs 35.5%; p < 0.05) showing a superimposable detection rate for cancer (18.7% vs 22%). Therefore, the significantly reduction of PSA levels in comparison with physiological PSA fluctuations (12) and the absence of reliable criteria to select patients at risk for PCa seems to suggest a prolonged trial of anti-inflammatory therapy before taking any decision in patients with negative prostate biopsy and persistently elevated PSA levels.

Our results deserve some considerations. Firstly, the absence of a placebo control group, for our purpose, we used as a surrogate our previously recorded cases. Secondly, it is unknown if PSA reduction is uniquely secondary to the anti-inflammatory activity or is in some way influenced by anti-proliferative effects of baicalina (25), thirdly, PCa incidence is available only in patients whose PSA levels remained unchanged after anti-inflammatory trial (the risk of missing PCa diagnosis in men with decreased PSA is actually unknown). Finally, a greater number of patients and a longer follow up are necessary to confirm our results.

In conclusion, in our preliminary data a prolonged oral anti-inflammatory therapy reduced PSA levels in selected patients (negative prostate biopsy and persistent elevated PSA values) decreasing the indication to perform repeat SPBx (about 30% of the cases).

REFERENCES
17. Nieder C, Norum J, Geinitz H. Impact of common medications...

Correspondence
Giuseppe Candiano, MD
Pietro Pepe, MD (Corresponding Author)
piepepe@hotmail.com
Francesco Pietropaolo, MD
Francesco Aragona, MD
Urology Unit - Cannizzaro Hospital, via Messina 829 - Catania, Italy

Archivio Italiano di Urologia e Andrologia 2013; 85, 2